4 Stocks to Watch on Monday: Micron, Mundy, AMC, ELF
PorAinvest
lunes, 11 de agosto de 2025, 9:08 am ET1 min de lectura
AMC--
Micron also raised its non-GAAP gross margin guidance to 44.0% to 45.0%, up from its earlier projection of 41.0% to 43.0%. Additionally, the company increased its non-GAAP earnings per share (EPS) forecast to $2.78 to $2.92, up from $2.35 to $2.65, and above the consensus estimate of $2.52. The company attributed the improved outlook to better pricing conditions, particularly in DRAM products, and strong execution across its operations [1].
Micron Executive Vice President and Chief Business Officer, Sumit Sadana, will provide further details during a fireside chat at the 2025 Keybanc Technology Conference in Park City, Utah, later today.
Investors should also keep an eye on other key stocks. Moderna (MNDY) has seen fluctuations in its stock price due to ongoing developments in its COVID-19 vaccine. AMC Entertainment (AMC) continues to attract attention as the company navigates the challenges of the movie theater industry. Elanco Animal Health (ELAN) reported strong Q2 2025 results, with 5% year-over-year revenue growth and a significant increase in innovation revenue, positioning it for continued growth [2, 3].
As the market awaits key inflation reports, investors are closely monitoring the economic indicators that could impact stock performance. Micron's positive guidance and Elanco's strong performance provide a positive outlook for these companies, but the broader market sentiment remains influenced by macroeconomic factors.
References:
[1] https://uk.finance.yahoo.com/news/micron-stock-rises-boosting-guidance-124810300.html
[2] https://www.ainvest.com/news/micron-technology-stock-grown-10-years-2508/
[3] https://www.ainvest.com/news/elanco-animal-health-q2-2025-innovation-driven-growth-accelerated-deleveraging-justify-buy-rating-2508/
ELAN--
MNDY--
MRNA--
MU--
Micron Technology (MU) stock rose on Monday, while investors await key inflation reports. Other stocks to watch include Moderna (MNDY), AMC Entertainment (AMC), and Elanco Animal Health (ELF).
Micron Technology (MU) stock surged 5.6% in pre-market trading on Monday, driven by the company's positive fourth-quarter fiscal 2025 guidance. The Boise, Idaho-based memory chipmaker revised its revenue forecast to $11.1 to $11.3 billion, an increase from its previous guidance of $10.4 to $11.0 billion. This new outlook exceeds analysts' consensus estimates of $10.74 billion [1].Micron also raised its non-GAAP gross margin guidance to 44.0% to 45.0%, up from its earlier projection of 41.0% to 43.0%. Additionally, the company increased its non-GAAP earnings per share (EPS) forecast to $2.78 to $2.92, up from $2.35 to $2.65, and above the consensus estimate of $2.52. The company attributed the improved outlook to better pricing conditions, particularly in DRAM products, and strong execution across its operations [1].
Micron Executive Vice President and Chief Business Officer, Sumit Sadana, will provide further details during a fireside chat at the 2025 Keybanc Technology Conference in Park City, Utah, later today.
Investors should also keep an eye on other key stocks. Moderna (MNDY) has seen fluctuations in its stock price due to ongoing developments in its COVID-19 vaccine. AMC Entertainment (AMC) continues to attract attention as the company navigates the challenges of the movie theater industry. Elanco Animal Health (ELAN) reported strong Q2 2025 results, with 5% year-over-year revenue growth and a significant increase in innovation revenue, positioning it for continued growth [2, 3].
As the market awaits key inflation reports, investors are closely monitoring the economic indicators that could impact stock performance. Micron's positive guidance and Elanco's strong performance provide a positive outlook for these companies, but the broader market sentiment remains influenced by macroeconomic factors.
References:
[1] https://uk.finance.yahoo.com/news/micron-stock-rises-boosting-guidance-124810300.html
[2] https://www.ainvest.com/news/micron-technology-stock-grown-10-years-2508/
[3] https://www.ainvest.com/news/elanco-animal-health-q2-2025-innovation-driven-growth-accelerated-deleveraging-justify-buy-rating-2508/

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios